Literature DB >> 9449496

Can a threshold limit value for natural rubber latex airborne allergens be defined?

X Baur1, Z Chen, H Allmers.   

Abstract

BACKGROUND: Recent studies have shown that systemic or respiratory occupational responses to latex can be induced by inhalation of latex aeroallergens.
OBJECTIVE: Our objectives were to study the relationship between exposure to different latex aeroallergen levels and type I allergic reactions in subjects with occupational contact with latex and to assess a threshold value for latex airborne allergens required for sensitization and symptom elicitation.
METHODS: We screened 145 subjects working in 32 hospitals or operating rooms with different latex aeroallergen levels. The quantified latex aeroallergen concentrations in the 32 rooms were compared with latex-related allergic symptoms.
RESULTS: Different latex aeroallergen concentrations could be detected in rooms where powdered latex gloves were used and no effective ventilation systems were installed. In environments with latex aeroallergen levels of 0.6 ng/m3 or greater, the reported workplace-related symptoms were significantly increased (p < 0.02). All 22 subjects with latex-specific IgE antibodies worked in rooms contaminated with latex aeroallergens (p < 0.05).
CONCLUSIONS: Our results demonstrate that symptoms and presence of latex-specific IgE antibodies in subjects are significantly associated with measurable levels of latex aeroallergens. A latex aeroallergen level of 0.6 ng/m3 is a critical threshold, especially for health care workers who are sensitized to natural rubber latex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449496     DOI: 10.1016/S0091-6749(98)70188-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Agents, old and new, causing occupational asthma.

Authors:  C E Mapp
Journal:  Occup Environ Med       Date:  2001-05       Impact factor: 4.402

Review 2.  Monitoring personal allergen exposure.

Authors:  T O'Meara; E Tovey
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

3.  Have health conditions associated with latex increased since the issuance of universal precautions?

Authors:  Brian P McCall; Irwin B Horwitz; John D Kammeyer-Mueller
Journal:  Am J Public Health       Date:  2003-04       Impact factor: 9.308

Review 4.  Primary prevention of latex related sensitisation and occupational asthma: a systematic review.

Authors:  A D LaMontagne; S Radi; D S Elder; M J Abramson; M Sim
Journal:  Occup Environ Med       Date:  2006-02-09       Impact factor: 4.402

5.  Effectiveness of a nationwide interdisciplinary preventive programme for latex allergy.

Authors:  Ute Latza; Frank Haamann; Xaver Baur
Journal:  Int Arch Occup Environ Health       Date:  2005-05-11       Impact factor: 3.015

Review 6.  [Dermatologic occupationally relevant type I allergies].

Authors:  V Mahler; H Drexler
Journal:  Hautarzt       Date:  2004-01       Impact factor: 0.751

7.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

8.  Residual Isocyanates in Medical Devices and Products: A Qualitative and Quantitative Assessment.

Authors:  Gillian Franklin; Homero Harari; Samavi Ahsan; Dhimiter Bello; David A Sterling; Jonathan Nedrelow; Scott Raynaud; Swati Biswas; Youcheng Liu
Journal:  Environ Health Insights       Date:  2016-10-13

Review 9.  EAACI position paper on occupational rhinitis.

Authors:  Gianna Moscato; Olivier Vandenplas; Roy Gerth Van Wijk; Jean-Luc Malo; Luca Perfetti; Santiago Quirce; Jolanta Walusiak; Roberto Castano; Gianni Pala; Denyse Gautrin; Hans De Groot; Ilenia Folletti; Mona Rita Yacoub; Andrea Siracusa
Journal:  Respir Res       Date:  2009-03-03

10.  The prevalence of latex sensitisation and allergy and associated risk factors among healthcare workers using hypoallergenic latex gloves at King Edward VIII Hospital, KwaZulu-Natal South Africa: a cross-sectional study.

Authors:  Shumani Makwarela Phaswana; Saloshni Naidoo
Journal:  BMJ Open       Date:  2013-12-09       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.